GTS-21

GTS-21 is a small-molecule drug candidate belonging to the class of nicotinic acetylcholine receptor ligands. Chemically it is a derivative of anabaseine, an alkaloid produced by certain marine worms, and it is often referred to by the alternative name DMXB-A, short for 3-[2,4-dimethoxybenzylidene]anabaseine. Its numeric designation reflects its origin in a collaborative medicinal-chemistry program. Although it interacts with more than one nicotinic receptor subtype, it is notable for behaving functionally as a partial agonist of the alpha-7 subtype ^[1][2].

The alpha-7 nicotinic acetylcholine receptor is widely expressed in the brain, where it takes part in attention, learning, and memory, and it is of interest in disorders marked by cognitive impairment ^[2][3]. Because this receptor is reduced or dysfunctional in schizophrenia and in Alzheimer's disease, agents that stimulate it, such as GTS-21, were proposed as a way to improve cognition. In laboratory and animal studies, GTS-21 improved measures of learning and memory and protected neurons under various forms of stress ^[1][3].

GTS-21 was investigated from the 1990s onward as a possible treatment for the cognitive deficits of schizophrenia and for neurodegenerative disease, and later for conditions including Alzheimer's disease, attention-deficit disorder, and inflammation ^[2][3]. In animal models it counteracted memory impairments produced by agents such as the anesthetic ketamine and by fragments of the amyloid-beta protein linked to Alzheimer's disease ^[2][3]. In human testing, however, the compound did not produce convincing, clinically meaningful improvements, and its development did not progress beyond mid-stage, phase II trials.

Beyond cognition, the alpha-7 receptor is a central element of what is called the cholinergic anti-inflammatory pathway, through which nervous-system signaling can restrain the release of inflammatory molecules, and GTS-21 has been used as a research tool to probe this role. GTS-21 remains an investigational compound; it is not an approved medicine and is not marketed for any indication. Its main significance today is as a prototype alpha-7 nicotinic agonist that helped shape understanding of the receptor and of the difficulty of translating such agents into effective therapies ^[2].

GTS-21 is a research compound with no approved human use. Phase 1 trials in healthy men found it generally well tolerated up to 150 mg twice a day, with nausea and headache being the usual complaints. Avoid it in pregnancy (not enough data), and be cautious if you have cardiovascular disease. There's a flagged interaction with oleic acid in certain lung-injury models (a7 stimulation made oleic acid-induced ARDS worse in animals, though what that means for people is unclear). No solid human drug interactions are on record, but be careful alongside other cholinergic or anticholinergic drugs. It's research-only, not approved by the FDA or EMA.

GTS-21, also known as DMXB-A, is a synthetic derivative of anabaseine, a toxin found in certain marine worms and ants. It was developed beginning in the 1990s by researchers including William Kem at the University of Florida, in collaboration with Taiho Pharmaceutical, as a selective partial agonist of the alpha7 nicotinic acetylcholine receptor. The rationale was that stimulating alpha7 receptors could enhance attention and memory and address the cognitive and sensory-gating deficits seen in schizophrenia and Alzheimer's disease, and the compound was carried into human clinical testing on that basis.

GTS-21 is one of the better known experimental alpha7 agonists and is viewed by the research community as a foundational tool compound for probing that receptor's role in cognition and inflammation. Clinical results have been mixed; some studies reported modest improvements in aspects of attention and sensory gating, while larger trials in schizophrenia produced disappointing or inconsistent cognitive benefits. Among nootropics enthusiasts it is respected for its clean, targeted mechanism and generally good tolerability in trials, but it remains a research chemical with limited availability, and expectations are tempered by the underwhelming clinical outcomes.